New Drug: Mirvetuximab Soravtansine in Advanced Ovarian Cancer
Study
A Phase III, Randomized, Open-label trial (MIRASOL)
|
Platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
|
Mirvetuximab soravtansine (n=227) vs SOC (n=226
|
|
Efficacy
mPFS: 5.91 vs. 4.34 mos, HR:0.72, p=0.0082
|
mOS: 16.46 vs. 12.75 mos, HR: 0.67, p=0.0046
|
ORR: 36.1% vs.14.6%, p<0.0001
|
Safety
Grade3: Keratophaty (9%vs.0), blurred vision (8% vs.0), neutropenia (1% vs.31%), thrombocytopenia (1% vs.27%).
|
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023
